

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10/699,874
Filing Date	2003-11-03
First Named Inventor	Arthur KUNZ
Art Unit	1642
Examiner Name	Brandon FETTEROLF
Attorney Docket Number	P194 1011.1

U.S. PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	5,714,586 (equivalent to WO 96/40261)		1998-02-03	American Cyanamid	
	2	7,355,011 (equivalent to WO 03/093320)		2008-04-08	UCB Pharma S.A	
	3	5,714,350		1998-02-03	Co	
	4	5,686,072		1997-11-11	Uhr	
	5	5,693,762		1997-12-02	Queen	
	6	6,183,744 (equivalent to WO 98/56418)		2001-02-06	Immunomedics, Inc.	
	7	5,382,510 (equivalent to WO 92/00311)		1995-01-17	The Trustees of Princeton University	
	8	7,541,034 (equivalent to WO 98/041641)		2009-06-02	The United States of America as represented by the Department of Health and Human Services	
	9	7,012,135 (equivalent to WO 01/94585)		2006-03-14	Celltech Chiroscience Limited	
	10	5,558,864 (equivalent to WO 92/15683)		1996-09-24	Merck Patent Gesellschaft Mit Beschränkter Haftung	
	11	6,180,377 (equivalent to WO 94/29451)		2001-01-30	Celltech Therapeutics Limited	
	12	7,115,723 (equivalent to WO 00/31141)		2006-10-03	Korea Institute of Science & Technology	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10/699,874
Filing Date	2003-11-03
First Named Inventor	Arthur KUNZ
Art Unit	1642
Examiner Name	Brandon FETTEROLF
Attorney Docket Number	P194 1011.1

13	5,225,539 (equivalent to EP 0239400)	1993-07-06	Medical Research Council
14	5,530,101 (equivalent to WO 90/07861)	1996-06-25	Protein Design Labs, Inc.
15	5,436,265 (equivalent to RU 2131423)	1995-07-25	Merck Frosst Canada, Inc.
16	7,129,053 (equivalent to WO 01/027612)	2006-10-31	Reiter
17	7,147,851 (equivalent to WO 98/006248)	2006-12-12	Ponath
18	6,777,390 (equivalent to WO 99/066031)	2004-08-17	Matthiessen
19	5,789,554 (equivalent to WO 96/004925)	1998-08-04	Leung

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S. PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	2006/0073137 (equivalent to WO 91/09967)		2006-04-06	Celltech R&D Limited	
	2	2002/0141990 (equivalent to WO 98/19704)		2002-10-03	SmithKline Beecham Corp	
	3	2007/0172920 (equivalent to JP 10-505231)		2007-02-22	Leung	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10/699,874
Filing Date	2003-11-03
First Named Inventor	Arthur KUNZ
Art Unit	1642
Examiner Name	Brandon FETTEROLF
Attorney Docket Number	P194 1011.1

	4	2005/0095238 (equivalent to WO 01/078779)		2005-05-05	Brettman	
--	---	---	--	------------	----------	--

If you wish to add additional U.S. Published Application citation information please click the Add button



FOREIGN PATENT DOCUMENTS



Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	
	1	96/005306 (equivalent to RU 9710420 A)	WO		1996-02-22	Myriad Genetics, Inc.		
	2	98/56418	WO		1998-12-17	Genetech, Inc.		

If you wish to add additional Foreign Patent Document citation information please click the Add button



NON-PATENT LITERATURE DOCUMENTS



Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	
	1	Benhar et al., "Mutations of two lysine residues in the CDR loops of a recombinant immunotoxin that reduce its sensitivity to chemical derivatization," <i>Bioconjugate Chem.</i> , 1994, 5: 321-326. (Abstract only)	<input type="checkbox"/>
	2	Browning et al., "B cells move to centre stage: novel opportunities for autoimmune disease treatment," <i>Nat. Rev. Drug Discov.</i> , 2006, 5: 564-576.	
	3	Carnahan et al., "Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties," <i>Clinical Cancer Res.</i> , 2003, 9, suppl.: 3982s-3990s.	
	4	DiJoseph et al., "Antibody-targeted chemotherapy of B-cell lymphoma using calicheamicin conjugated to murine or humanized antibody against CD22," <i>Cancer Immunol. Immunother.</i> , 2005, 54: 11-24.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10/699,874
Filing Date	2003-11-03
First Named Inventor	Arthur KUNZ
Art Unit	1642
Examiner Name	Brandon FETTEROLF
Attorney Docket Number	P194 1011.1

5	DiJoseph et al., "Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies," <i>Blood</i> , 2004, 103: 1807-1814.
6	Leung et al., "Construction and characterization of a humanized, internalizing, B-cell (CD22)-specific, leukemia/lymphoma antibody, LL2," <i>Mol. Immunol.</i> , 1995, 32: 1413-1427. (Abstract only)
7	Leung et al., "Effect of Vk framework-1 glycosylation on the binding affinity of lymphoma-specific murine and chimeric LL2 antibodies and its potential use as a novel conjugation site," <i>Intl. J. Cancer.</i> , 1995, 60: 534-538. (Abstract only)
8	Riechmann et al., "Reshaping human antibodies for therapy," <i>Nature</i> , 1988, 332:323-327. (Abstract only)
9	Vaughan et al., "Human antibodies by design," <i>Nature Biotech.</i> , 1998, 16: 535-539. (Abstract only)
10	van Rossenberg et al., "A structure-function study of ligand recognition by CD22 beta," <i>J. Bio. Chem.</i> , 2001, 276: 12967-12973.
11	Verhoeyen et al., "Reshaping human antibodies: Grafting an antilysozyme activity," <i>Science</i> , 1988, 239:1534-1536. (Abstract only)
12	Vose, J.M., "Therapeutic uses of MAbs directed against CD20" <i>Cytotherapy</i> , 2000, 2:455-461. (Abstract only)

If you wish to add additional non-patent literature document citation information please click the Add button

Add

EXAMINER SIGNATURE

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Not for submission under 37 CFR 1.99)

Application Number	10/699,874
Filing Date	2003-11-03
First Named Inventor	Arthur KUNZ
Art Unit	1642
Examiner Name	Brandon FETTEROLF
Attorney Docket Number	P194 1011.1

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.